A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection

• ClinicalTrials.gov Identifier: NCT05467553
• Recruitment Status: Not yet recruiting
• First Posted: July 20, 2022
• Last Update Posted: December 29, 2022
• Sponsor: National Taiwan University Hospital
• Collaborator: PharmaEssentia
• Information provided by (Responsible Party): National Taiwan University Hospital

Study Description

Brief Summary:

This is an open-label, randomized, multi-center study in patients with chronic HBV and HDV co-infection.

Condition or disease	Intervention/treatment	Phase
Hepatitis D	Drug: Ursodeoxycholic acid; Drug: Ropeginterferon alfa-2b; Drug: Tenofovir Alafenamide	Phase 2

Detailed Description:

There will be 2 treatment groups in this study, 15 subjects per group as follows:

Group 1: TAF 25 mg orally (PO) QD for 60 weeks with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.

Group 2: Ursodeoxycholic Acid (UDCA)* 15 mg/kg orally (PO) QD plus TAF 25 mg orally (PO) QD for 60 weeks, with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.

Both groups will have a post-treatment follow-up of 24 weeks.

*: Dose of Ursodeoxycholic Acid (UDCA) will be determined by weight at Day 1 (TW0) in 2-4 divided doses.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 30 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open-label, Randomized Study to Compare the Efficacy and Safety of P1101 Plus Tenofovir Alafenamide With or Without Ursodeoxycholic Acid in Patients With Chronic Hepatitis B and Hepatitis D Virus Co-Infection
• Estimated Study Start Date: February 24, 2023
• Estimated Primary Completion Date: February 28, 2025
• Estimated Study Completion Date: August 31, 2025

Arms and Interventions

Arm	Intervention/treatment
Experimental: TAF and P1101 combination therapy with UDCA; Ursodeoxycholic Acid (UDCA) 15 mg/kg orally (PO) QD plus TAF 25 mg orally (PO) QD for 60 weeks, with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.	Drug: Ursodeoxycholic acid; Ursodeoxycholic Acid 15 mg/kg PO QD for 60 weeks; Other Name: Uroso Tablets; Drug: Ropeginterferon alfa-2b; P1101 450 µg SC Q2W add-on at treatment week 12 for 48 weeks; Other Name: BESREMI; Drug: Tenofovir Alafenamide; TAF 25 mg PO QD for 60 weeks; Other Name: Vemlidy
Active Comparator: TAF and P1101 combination therapy without UDCA; TAF 25 mg orally (PO) QD for 60 weeks with P1101 450 µg sub-cutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.	Drug: Ropeginterferon alfa-2b; P1101 450 µg SC Q2W add-on at treatment week 12 for 48 weeks; Other Name: BESREMI; Drug: Tenofovir Alafenamide; TAF 25 mg PO QD for 60 weeks; Other Name: Vemlidy

Outcome Measures

Primary Outcome Measures :

1. HDV RNA level [ Time Frame: Week 60 ]
   Decline in HDV RNA ≥ 2 log10 IU/mL at Week 60
2. ALT level [ Time Frame: Week 60 ]
   ALT normalization (ALT < upper limit of normal) at Week 60

Secondary Outcome Measures :

1. Undetectable HDV RNA [ Time Frame: Week 60 and Week 84 ]
   Undetectable HDV RNA (HDV RNA< low limit of quantifica-tion) at Week 60 and Week 84
2. HBsAg level [ Time Frame: Week 60 and Week 84 ]
   Reduction in HBsAg ≥ 1 log10 IU/mL at Week 60 and Week 84
3. Undetectable HBsAg [ Time Frame: Week 60 and Week 84 ]
   HBsAg loss at Week 60 and Week 84
4. HBsAg and anti-HBs level [ Time Frame: Week 60 and Week 84 ]
   HBsAg seroconversion (HBsAg loss plus positive anti-HBs) at Week 60 and Week 84
5. HDV RNA level [ Time Frame: Week 84 ]
   Decline in HDV RNA ≥ 2 log10 IU/mL at Week 84
6. ALT level [ Time Frame: Week 84 ]
   ALT normalization (ALT < upper limit of normal) at Week 84

Eligibility Criteria

• Ages Eligible for Study: 20 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Positive for HBsAg for at least 6 months, either HBeAg(+) or HBeAg(-), and positive for anti-HDV with detectable HDV RNA and ALT ≥ ULN to ≤ 10X ULN at screening.
2. Interferon treatment naïve.
3. Willing and able to provide written informed consent.
4. Age 20-75 years old; subjects who are over 70 years of age must be in generally good health.
5. Laboratory test results before study entry: WBC ≥ 3,000/mm3; ANC ≥ 1,500/mm3; Platelet ≥ 90,000/mm3; Hemoglobin ≥ 10g/dL; e-GFR ≥ 60mL/min.
6. ECG without clinically significant abnormalities before study entry.
7. Be able to attend all scheduled visits and to comply with all study procedures.

8. Patients with anti-HCV(+) or anti-HIV(+) can be enrolled if:

   1. anti-HCV(+) with undetectable HCV RNA ≥ 3 months.
   2. anti-HIV(+) with undetectable HIV viral load (either with or without Highly Active Anti- Retroviral Therapy, HAART).

Exclusion Criteria:

1. Clinically significant illness or surgery that might interfere with study participation.
2. Clinically significant vital sign abnormalities, uncontrolled hypertension, or fever [body temperature >38 degrees Celsius].
3. History of significant alcohol or drug abuse within 6 months prior to the screening visit (alcohol consumption of more than 14 units of alcohol per week [1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]) or refusal to abstain from alcohol or illicit drugs throughout the study.
4. Any history or presence of poorly controlled or clinically significant medical conditions that are not suitable to receive interferon-based treatment, at the discretion of the investigator: major psychiatric (including but not limited to those with severe depression, severe bi-polar disorder, schizophrenia, suicidal ideation or history of suicidal attempt), neurological, cardiovascular, pulmonary, hematologic, immunologic, autoimmune diseases, thyroid or other endocrine diseases, metabolic (e.g. diabetes mellitus with HbA1C > 8.0%) or other uncontrolled systemic disease, coagulation disorders or blood dyscrasias.
5. Pregnant subject; female subject who are breast feeding or lactating; female subject or the spouse of male subject, with child-bearing potential who is unwilling or unable to practice adequate contraception, defined as vasectomy in men, tubal ligation in women, or use of condoms and spermicides, or birth control pills, or intrauterine devices throughout the study.
6. History of severe allergic or hypersensitivity reactions, e.g. hypersensitivity to the active substance or to any of the excipients of ropeginterferon alfa 2b, ursodeoxycholic acid, tenofovir disoproxil fumarate and tenofovir alafenamide.
7. Therapy with any systemic anti-viral treatment, anti-neoplastic, or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) within 1 month (3 months for those with long elimination half-lives) prior to the first dose of study drug.
8. A depot injection or an implant of any drug within 3 months prior to administration of study medication, other than contraception or hyaluronic acid injections in joints for osteoarthritis.
9. Body organ transplant or taking immunosuppressant.
10. Use of an investigational drug within 4 weeks prior to the first dose of the study drug.
11. History of malignancy diagnosed or treated within 5 years prior to screening (except for localized treatment of squamous or non-invasive basal cell skin cancers; cervical carcinoma in situ); cancer survivors not on maintenance therapy within the past 5 years.
12. History of opportunistic infection (e.g., invasive candidiasis or pneumocystis pneumonia).
13. Serious localized infection (e.g., cellulitis, abscess) or systemic and life-threatening infection (e.g., septicemia) within 3 months prior to screening.
14. Clinically significant medical conditions known to interfere absorption, distribution, metabolism or excretion of the study drugs.
15. Decompensated liver disease, which includes but not limited to the following: total bilirubin ≥ 2 mg/dL (except in Gilbert syndrome), direct bilirubin ≥ 2X ULN, albumin level < 3.5 g/dL, INR ≥ 1.5; clinical evidence of ascites, liver decompensation, hepatic encephalopathy, oesophageal varices or cirrhosis as identified by ultrasound or any other examination before study entry.
16. Significant steatohepatitis by ultrasound or other examination at the discretion of investigator.
17. Other form of significant chronic liver diseases, except those mentioned above.
18. Significant or major fundoscopic findings at screening including but not limited to retinal exudates, hemorrhage, detachment, neovascularization, papilloedema, optic atrophy, microaneurysms and macu-lar changes.
19. Patients with complete biliary obstruction, chololithiasis, severe pancreatic disease or peptic ulcer.
20. Patients treated by monotherapy of telbivudine/TDF/TAF/adefovir dipivoxil or any other combination therapy with telbivudine/TDF/TAF/adefovir dipivoxil within 1 month prior to screening.
21. Patient who vaccination with any live attenuated vaccine within 1 month prior to screening.

Contacts and Locations

Contacts

Contact: Pei-Jer Chen; 886-2-23123456 ext 67072; peijerchen@ntu.edu.tw

Locations

Taiwan

National Taiwan University Hospital

Taipei, Taiwan

Contact: Pei-Jer Chen 886-2-23123456 ext 67072 peijerchen@ntu.edu.tw

Taipei Medical University Hospital

Taipei, Taiwan

Contact: Yi-Wen Huang 886-2-27372181 ext 3577 yiwenhuang@tmu.edu.tw

Sponsors and Collaborators

National Taiwan University Hospital

PharmaEssentia

Investigators

• Principal Investigator: Pei-Jer Chen; National Taiwan University Hospital

More Information

• Responsible Party: National Taiwan University Hospital
• ClinicalTrials.gov Identifier: NCT05467553
• Other Study ID Numbers: 202108021MIPD; P1101-HDV ( Other Identifier: PharmaEssentia Corporation )
• First Posted: July 20, 2022
• Last Update Posted: December 29, 2022
• Last Verified: July 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by National Taiwan University Hospital:

Ropeginterferon alpha-2b, Hepatitis D, UDCA, TAF

Additional relevant MeSH terms:

Hepatitis A; Hepatitis D; Hepatitis; Hepatitis, Viral, Human; Coinfection; Infections; Liver Diseases; Digestive System Diseases; Virus Diseases; Enterovirus Infections; Picornaviridae Infections; RNA Virus Infections; Tenofovir; Ursodeoxycholic Acid; Antiviral Agents; Anti-Infective Agents; Reverse Transcriptase Inhibitors; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Anti-HIV Agents; Anti-Retroviral Agents; Cholagogues and Choleretics; Gastrointestinal Agents